-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ie+CoBkyL9BCz4YwVXu9ZXp9gKZ2/cJXBDxxYqFPo05k10bCz3+Cp0fOGoDmWGtG
 vcqlXQtO8hwZbvemHww+EA==

<SEC-DOCUMENT>0001075880-07-000029.txt : 20070601
<SEC-HEADER>0001075880-07-000029.hdr.sgml : 20070601
<ACCEPTANCE-DATETIME>20070601095150
ACCESSION NUMBER:		0001075880-07-000029
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070601
FILED AS OF DATE:		20070601
DATE AS OF CHANGE:		20070601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		07892656

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20070601.htm
<DESCRIPTION>FORM 6K 2007-06-01
<TEXT>
<html>

  <head>
    <title>form6k20070601.htm</title>
<!-- Licensed to: Novogen-->
<!-- Document Created using EDGARizer 4.0.1.0 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br><br>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman;"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>______________________________________________</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>Form
      6-K</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>REPORT
      OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
      THE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
      EXCHANGE ACT OF 1934</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">For
      the
      month of June, 2007</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Commission
      File Number <font style="DISPLAY: inline; FONT-FAMILY: Arial, sans-serif;">________________</font></font></div>
    <div><br></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman;"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Translation
      of registrant&#8217;s name into English)</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;">140
      Wicks
      Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Address
      of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">___________________________________</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover of Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Form
      20-F
<font style="DISPLAY: inline;" face="Wingdings"><strong>x</strong></font><strong>&#160;</strong>Form
      40-F <font style="DISPLAY: inline;" face="Wingdings"><strong>o</strong></font></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(l):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Note:
      Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
      6-K if submitted solely to provide an attached annual report to security
      holders.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule lO1(b)(7):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Note:
      Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
      6-K
      if submitted to furnish a report or other document that the registrant foreign
      private issuer must furnish and make public under the laws of the jurisdiction
      in which the registrant is incorporated, domiciled or legally organized (the
      registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
      which the registrant&#8217;s securities are traded, as long as the report or other
      document is not a press release, is not required to be and has not been
      distributed to the registrant&#8217;s security holders, and, if discussing a material
      event, has already been the subject of a Form 6-K submission or other Commission
      filing on EDGAR.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline;" face="Wingdings"><strong>o</strong></font><strong>&#160;</strong>No
      <font style="DISPLAY: inline;" face="Wingdings"><strong>x</strong></font></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b):</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf </strong>by the undersigned,
      thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>/s/&#160;&#160;Ron
      Erratt</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Ronald
      Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Company
      Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Date
      1 June, 2007</strong></font></div>
    <div><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><img src="novogen6.jpg" alt=""></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>ASX
      &amp; MEDIA RELEASE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>1
      JUNE, 2007</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>PHASE
      III TRIAL FOR PHENOXODIOL TO RECRUIT NEARLY 500 PATIENTS WITH RECURRENT OVARIAN
      CANCER AT 60 HOSPITALS WORLDWIDE</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Novogen
      Limited&#8217;s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has made the
      following announcement:</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>OVArian
      TUmor REsponse (&#8220;OVATURE&#8221;) trial enrolls first US patient</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Dallas,
      Texas, May 30 &#8211; Researchers at the Harold C. Simmons Comprehensive Cancer Center
      at the University of Texas Southwestern Medical Center (UTSMC) have enrolled
      the
      first US patient in the worldwide clinical trial looking at oral phenoxodiol
      in
      combination with carboplatin for the treatment of recurring ovarian
      cancer.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Phenoxodiol
      has been shown in laboratory testing to be successful in restoring sensitivity
      of cancer cells from patients with ovarian cancer who have become resistant
      to
      standard chemotherapy drugs.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">At
      UTSMC,
      the OVATURE trial will be led by John Schorge, MD, Associate Professor of
      gynecologic oncology.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">"Earlier
      clinical studies have shown that phenoxodiol has an excellent safety profile,
      with few side effects, and that it appears to re-establish the sensitivity
      needed for chemotherapy drugs to work," said Dr&#160;Schorge.&#160;&#160;&#8220;We&#8217;re
      proud to be part of this trial because the advances in ovarian cancer are few
      and far between.&#160;&#160;We hope we can play a leadership role in finding
      ways to beat this deadly disease.&#8221;</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">This
      Phase III study will recruit 470 patients at approximately 30 centers in the
      United States and 30 hospitals throughout Europe and
      Australia.&#160;&#160;Phenoxodiol, a capsule taken by mouth, is an
      investigational drug that has not yet been approved by the FDA.&#160;&#160;In
      the OVATURE trial, patients are randomly divided into two groups and receive
      either oral phenoxodiol in combination with carboplatin (a standard chemotherapy
      drug) or carboplatin with an inactive control capsule.&#160;&#160;Neither
      patient nor doctor will know which group each patient is in.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">All
      patients will receive carboplatin on a weekly basis, instead of receiving the
      customary carboplatin treatment of one intravenous infusion every three weeks,
      because some studies have shown that patients whose tumors have become resistant
      to the three-week standard regimen of carboplatin may respond to the weekly
      administration of the drug.&#160;&#160;Accordingly, researchers hope that
      patients on both arms of the trial may benefit.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">&#8220;This
      is
      the first of many prestigious U.S. institutions which will be participating
      in
      this trial,&#8221; said Dr&#160;Patti&#160;Rossi, Vice President, Clinical Operations,
      Marshall Edwards, Inc.&#160;&#160;&#8220;Patients nationwide should have access to
      this trial, with as little disruption to their daily lives as
      possible.&#160;&#160;Accordingly, we&#8217;re working with institutions across the US
      which will be joining the trial shortly.&#8221;</font></div>
    <div><br></div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>About
      Chemo-Resistant Ovarian Cancer</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">In
      many
      patients with ovarian cancer, cancer cells develop resistance to standard
      chemotherapy drugs, known as "chemoresistance," making it difficult to
      successfully manage and treat cancer.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">According
      to the Ovarian Cancer National Alliance:</font></div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top">
            <td align="right" style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Ovarian
                cancer, the deadliest of the gynecologic cancers, is the fifth leading
                cause of cancer death among U.S. women. Ovarian cancer occurs in
                1 out of
                69 women;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top">
            <td align="right" style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">About
                20,000 women are diagnosed with the disease each
                year;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top">
            <td align="right" style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">About
                15,000 women in the United States die from ovarian cancer each
                year;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top">
            <td align="right" style="WIDTH: 36pt">
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;&#160;&#160;</font></div>
            </td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Currently,
                55 percent of the women diagnosed with ovarian cancer die from it
                within
                five years; among black women only 40 percent survive five years
                or
                more.<sup><a href="#ref.id4918274">*</a></sup></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>About
      Phenoxodiol</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Phenoxodiol
      has shown the ability to kill cancer cells that are relatively resistant to
      standard chemotherapy drugs in laboratory studies.&#160;&#160;The ability of
      phenoxodiol to overcome chemoresistance is thought to be due to its potential
      to
      disrupt various resistance mechanisms the cancer cell has
      developed.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">In
      2004,
      phenoxodiol received fast track designation by the FDA for refractory ovarian
      cancer.&#160;&#160;Fast track allows for the expedited development of drugs that
      are intended to treat serious or life-threatening conditions and that
      demonstrate a potential to address unmet medical needs.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>About
      MEI</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Marshall
      Edwards Inc. is a leading biotechnology company in the development of cancer
      therapies.&#160;&#160;MEI is currently developing a range of anti-cancer
      therapies that represent the next generation of oncology drugs.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Marshall
      Edwards Inc. (Nasdaq: MSHL) is 78.1 percent owned by the pharmaceutical company,
      Novogen Limited (NASDAQ: NVGN;&#160;&#160;&#160;ASX: NRT), from which it
      licenses phenoxodiol. More information on phenoxodiol and on the company can
      be
      found at www.marshalledwardsinc.com&#160;and www.novogen.com</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><sup>*</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">&#160;</font>Sources:&#160;&#160;U.S.
        Cancer Statistics Working Group. United States Cancer Statistics: 2003 Incidence
        and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human
        Services, Centers for Disease Control and Prevention and National Cancer
        Institute; 2006. Available at:
<u>htttp://www.cdc.gov/cancer/npcr/uscs</u>.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font style="DISPLAY: inline; FONT-SIZE: 10pt;">Ries
        L</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">A</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">G,
        Harkins D, Krapcho M, Mariotto
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">A</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">,
        Miller B</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">A</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">,
        Feuer EJ, Clegg L, Eisner MP, Horner
        MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds). SEER Cancer Statistics
        Review, 1975-2003, National Cancer Institute. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">Bethesda</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">MD.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">A</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">vailable
        at: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt;"><u>http://seer.cancer.gov/csr/1975_2003/</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">.
        Based on November 2005 SEER data
        submission, posted to the SEER web site 2006.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div>&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><em>Under
      U.S. law, a new drug cannot be marketed until it has been investigated in
      clinical trials and approved by the FDA as being safe and effective for the
      intended use. Statements included in this press release that are not historical
      in nature are "forward-looking statements" within the meaning of the "safe
      harbor" provisions of the Private Securities Litigation Reform Act of 1995.
      You
      should be aware that our actual results could differ materially from those
      contained in the forward-looking statements, which are based on management's
      current expectations and are subject to a number of risks and uncertainties,
      including, but not limited to, our failure to successfully commercialize our
      product candidates; costs and delays in the development and/or FDA approval,
      or
      the failure to obtain such approval, of our product candidates; uncertainties
      in
      clinical trial results; our inability to maintain or enter into, and the risks
      resulting from our dependence upon, collaboration or contractual arrangements
      necessary for the development, manufacture, commercialization, marketing, sales
      and distribution of any products; competitive factors; our inability to protect
      our patents or proprietary rights and obtain necessary rights to third arty
      patents and intellectual property to operate our business; our inability to
      operate our business without infringing the patents and proprietary rights
      of
      others; general economic conditions; the failure of any products to gain market
      acceptance; our inability to obtain any additional required financing;
      technological changes; government regulation; changes in industry practice;
      and
      one-time events. We do not intend to update any of these factors or to publicly
      announce the results of any revisions to these forward-looking
      statements.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">#
      #
      #</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font style="DISPLAY: inline; FONT-SIZE: 10pt;">Bethesda</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">,
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">MD.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">A</font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">vailable
      at: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt;"><u>http://seer.cancer.gov/csr/1975_2003/</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt;">.
      Based on November 2005 SEER data
      submission, posted to the SEER web site 2006.</font></font></div>
    <div><br>
      <hr>
    </div>
    <div><a name="ref.id4918274">&#160; </a>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>ISSUED
      FOR:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOVOGEN
      LIMITED</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>LISTINGS:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ASX
      (CODE NRT), NASDAQ (CODE NVGN).</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>FOR
      FURTHER</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>INFORMATION:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CHRISTOPHER
      NAUGHTON, MANAGING DIRECTOR, NOVOGEN LIMITED</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><font id="TAB1" style="MARGIN-LEFT: 144pt;"></font><strong>TEL
      (02) 9878
      0088</strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>http://www.novogen.com</u></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>ISSUED
      BY</strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WESTBROOK
      COMMUNICATIONS</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">CONTACT:
      DAVID REID TEL (02) 9231 0922 OR 0417 217 157</font></div>
    <div><br></div>
    <div><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br></body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogen6.jpg
<TEXT>
begin 644 novogen6.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!P17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@#`P#$!`@`9````3@``````
M``!@`````0```&`````!````141'05)I>F5R(%-O9G1W87)E(%-U:71E`(#_
MVP!#``(!`0$!`0(!`0$"`@("`@0#`@("`@4$!`,$!@4&!@8%!@8&!PD(!@<)
M!P8&"`L("0H*"@H*!@@+#`L*#`D*"@K_VP!#`0("`@("`@4#`P4*!P8'"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@K_P``1"`"G`<(#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#]_****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"N)TG7(#\<-=\*JP5H?"VEW*1XYP]SJ2D_^0Q7;5\K^(OC3;^!?^"L>A_"
M_5+E$C\<_!QTTR)I<;[NQO[B9E''S,8I9&`XP(R><\7%-[')BJT*+@Y/=I'U
M);'Y-O<`9J2JUA,T^Y]@"E5VD-G/7^F/SJS4O<Z[W"BBBD`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!7X]_\`!?\`^*7BK]FW]NCX#?M&>"9BM]X?TVZGC/.V18KF,R1G'9D=
MD)Z[6/K7["=:_';_`(.DO#@C/PB\8",X@.J6*MV^80N!_P"0Z[\M498M1:NF
M?+<82E2R:56'Q1::/U'_`&7?CGX)_:2^"/A_XV_#W4%N-*\0:7!=0@'YH6*#
M=$X[.C94CU!KT+(/0U_/E_P12_X*C2_L8_$5_@K\6=5_XMWXIOX\74B?\@6\
M9BHF&#S&V[Y^"?D4]`:_?7P_KNEZ_I$6M:)?Q75K<PK);7$+;DE1AD,I'!!'
M(]0:C'86>&JOL;\.9[A\YP*DI>_%*Z-BBCI17&?1!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`449'K10`4444`%%%%`!1110`4444`%%&0>AHH`
M***,@]#0`5^87_!SIX*DU?\`9,\&^-4CR-'\;+"YV<J)[>4`Y],Q'\Q7Z>U\
M9?\`!<_X5M\0O^"9?Q"2RM3+<Z$+#6+968D@07D+3'/M#YWYUTX.3AB8R1XG
M$5%XC):\%ORM_<?SGF3R6,!7((PQSU!SD?C7Z8?\$8?^"QU_\#-7L?V6OVH/
M$C/X-N1Y/A?Q%?SD_P!CS,V5MI6.3Y#$L`3]S`'0"OS,G1@0Q;)R<^XZ`_F#
M3S=)*@5U'`(!QR*^NQ%&&)ARR/P'*<VQ.2XR-:CTW1_7AIFNV6K6D=[8S1RQ
M2*"DB2`JP(R"#T(]".#5Q6W?_KK\5?\`@B)_P5VO/`VN:9^QY^T[XHEET6[G
M\CP7XEOI<_8VV#9:2N?^69;Y4)R59U0GFOVCL)4E3S$;(95*\Y&.>]?(XO#3
MPM7E9_0&29SA\YP:K4WKU78L4445S'LA1110`4449%`!111D>M`!1110`449
M'3-%`!1110`4444`%%&1ZT4`%%&1ZT4`%%!('4T4`%%%%`!11D>M&1ZB@`HH
MR#T-%`!1110`449`ZFC(]:`"BBB@`HHR!U-%`!1110!CCQ;X:;Y5UVR)/11,
M.:N:;JFFZ@C/97<4R@`DPG<._I]#7\L3Z[J[J4;5;O!ZXN#7Z`_\$-/V_KOX
M3_$^3]F+XG:T&T3Q=>)_PCEU=S$+9:FQ*K""<X28E5`SPX`&=_'@8?/J5>NJ
M;5KGZGGWA;CLEP,\13J^TY5>R70_:=65E#J>#TI:J6U])+"K_9^&4L.<=^E6
MQTKWS\KOJ(V`<FLW5_$FB:4WDZEJD,#XR$=\''KBK\_0#-?C7_P<<ZAJ%C^T
M=X)6QNWB\WPPY8HQ'/G,,\$9/3KGI7+C,3]4H>T/>X:R&?$F<1P*ER\UW?TW
M/V#TG7M(UR#S])U&*YB5RK/"^X*<9P<=#R./>M.,`$L.X%?G1_P;C7&H7W[+
M?C*>_P!1FGQ\0IE3SY2Y5?L%EP"Q)QG<?^!5^BJ-MXQTHPM=8BBJO<Y,ZRQY
M+FM3!.7-R.UR2H97$:;V'%.,[`X*C\Z^>?VYO^"BWP6_8B^'O_"0^-;A;_7+
MQ&_L7PW:W2"XO&4X8Y_Y9HI/+GC/`R2`=ZE2%&'/-V1R87"8G'5XT</'FD]%
M8^@%O;91F255STR<9KA_'/[3W[/GP[NFL?&WQF\-:7,K;6AO=7AC=3Z$,V17
MX2?M3?\`!5W]K?\`:GU>YAN/']YX7\.3RNB:%X;O)+>,Q$`[99E(>7`X.Y@A
MSRO-<7\(OV#?VS_VA[=?$7P\^!GB?5+2?YEU6_A,$++TW1RW!C60<8RA8<<5
MXTLZC4J.%"#D?J.'\+7A*,:V;8J-)-7M=7/WPT+]NO\`9!\42+;Z'^T?X0F=
MVP@.N0J"?Q:O1]!\5^'O$%H-0T;7;.]MY,>5/9SB1'^A4D&OY\_%7_!)3_@H
M9X/TXZWJO[-VJW"1+ND_LV^M[F1![)'(9&^B@FO./AW\;/VGOV3/&[GP1XS\
M3>$-7MI@MUITC2P[BI.%FMY!AP/FX8'&3TS6+SNO3E:K2:1HO#++,?%O+\PC
M*72+:U/Z8O.\S)@8>N&%<E^T1\-;+XQ_`;Q=\+;JW2:/Q!X=O+`Q2?=8RPL@
MS^)%?!/_``3O_P""Z6@?%W5-/^$/[4MI9:#KEQB&R\3POLLKURV%1P?]0Y&,
M98@D'[N=H_1O[:MQ8F6T*RJ0<$-U!Z&O:PF,I5Z<:E+8_,L^X?S+**D\)C86
M=FK]'\S^1SQ#HE[X:U2X\-ZG$\=UI]P]M=1.FTI(F%88/3IT[<BJ-?4W_!9;
M]G^X_9]_X*"^/-,$&RR\2ZE)XBT\K'A2EY(TCJ.V%E\Q?H!TSBOEN-%<X9\?
MA7Z)AJT:E&+1_)V94)8;'U*;5K-DUHS9WB0JP!VL.H/]?ZU^X?\`P06_X*A7
M/Q^\$_\`#)OQU\1^=XP\,V"?\(WJ=VY:76+!`5VNQ^]/$`N3U=6#=0^/PV9R
M3QQ72_!SXL^.O@?\4=!^+7PVU>2PUS0-3BN["YC;'S*P)1A_$KKE&7H58@\&
MN?'8*.*@V]SU.&\\KY+CE):P>Z/ZU;<QM$/+'&.YJQTKQ#]@W]K'PO\`MA_L
MR^&?CGX7DA"ZI:E=2MUE):TNT++-$01G(<9&>JD&O;Z^-J1=.HX/H?T1AJ]/
M$X>-6GM)7#I4<L\,0WN3QZ*33I&((`&<@]Z\+_X*%?M'/^RU^RIXO^+<-TD-
MY;Z>;?1RSX)NY@8HL<'.'=6_X":RJ35.#D]D=>&H5,5B84::O*3LCUV?QOX3
MMLF?7[50OWBTX`'XUJ6TL<R^;$<AE!!QU!K^;S]@#X.>*?VG_P!L#P;\*QJ5
M^UE/J:W>LM'=,/*LX5\V0DCH#M,?^\P'>OZ-O#\)L-/AM$B(184"!CS]T<5Q
MX+&1QD.91L?2\5\-QX9Q,*'M>>4DI/R3-(G`ZU3:YLE(,THR>AP:\,_;C_X*
M&?!?]ACP0GB+XAW`OM6O&*:-X<L9P;J]8#J!_`@/!<\9(')(!_&C]K'_`(*X
M_M>_M0W]S;R>.[GPAX>D^6+0O#-]);@(3SYLX99)3Z\JI'&RHQF98?"RY'K+
ML5P_P9FW$252FE"EUE+8_=CQW^TK\`OAI<M9>//C%X<TJ>,9>WO-7A21!_M*
M6R/RKG-!_;N_8\\3W/V30OVC_"-Q(&P476H0<_BPK\"_A/\`L,_MC?M'6R:S
M\-_@1XAUBT?F/5I[<002AN=R23LBOTY*Y[9/2NM\3_\`!)'_`(*">'].:[N_
MV<;^^B@^\FG75K=2(3SS&DA)_`5P+.,8UI1=C["7AYD%"?LZV90Y_)Z']">D
M>*?#'B.QAU/1==L[RVN!F"XM;A7CD&,Y5E.#P.U7[9PY8AP1Q@"OYF/!'QF_
M:?\`V0OB`1X5\9^*O!NMVI'VO3[F66`L.0!-;O\`+(/<@CWS7Z<?\$Y_^"[6
MB_$K5+3X0?M96EEHFM7+Q0Z?XGB<QVEW(3M`F5LB%B=H#`["6QA>,].%SBA7
MER5%RR\SR,]\-\TRG#_6<+.->EU<=S]-:*K6.I1W\"W,&UT<91D?(;Z&K->P
M?G*=PH/2FRR&-=P7/':O(_VK?VT_@M^QU\/I_'WQDUU+1`=MC81.&N+V0CA(
MDZL>Y/11R3BIG.-.#G)V2-L/1K8JNJ-&+E)[)'J)O[2*,RRW2A=P'([GM7/>
M,_C5\)/A^BOXZ^)&B:0-F\#4M1CA.WUPY%?B)^UI_P`%LOVJ_P!H?49M$^%N
MMMX!\/898;?1ILWLBJ?O2W"\J2.=J;0,9SC->">"/V:_VO?VEKEM7\&?##QS
MXQ:X</)JK6MS<PR,Q)W//)\N3@\E@#CJ<5X<\ZO*V'AS(_3<O\,JSP_M<UQ4
M*'EU/Z"!^V_^R(SB)?VCO!Q+=`-<@Y_\>KJ_#?QX^"OC"X2S\*_%3PYJ4TA(
M2*QU>&5C@9/"L3T!K\"5_P""2G_!1<+]I'[+NJ$@<$ZGIY8?@9\UQ'C;]D']
MLCX+1MJ'C/X&^-M$MHL-)?V^DW7D]0`3+""@YP`<]3VZTEG&)7QTF=R\-\AK
MZ8?,X.79L_I174+25]B,C8&>/>K","N0N`.U?@+_`,$__P!O[]N?P3\;O"WP
MB^'_`(\OO$]KK>MV^F_\(]XDGENHXU:55;:[,9(BBLS,0Q`"\C@5^^6DO<2:
M7"]V`)3'^\"]-W?&:]3"8N&*H\]K-;GP/$W#&)X:Q4:56HIJ6JL^A:+*$!)^
ME9USXBT"TN7MKO5[:.0`$QRR@'!Z'!_G5R0%T4`]".W7FOQ)_P"#@/5=4L?V
MS-,M(-1G6-?"%NP6.8J-WFR@G'3)P/RIXO%+"4'5>I'#&0?ZQYI'!<_)=7N?
MM./%?AGOKEE_W_6D_P"$K\,_]!NR_P"_ZU_-G\+/V:?VL_C=X=;QA\(O@]XQ
M\1:5'</`^H:5932Q>:H4L@9006&\<5T__#`?_!0+_HV?XA?^"BX_^)KRXYS5
MDM*3/NZOAIE="JZ<\S@FM&K_`/!/Z)O^$J\-$9_MNRP.O[]:=!XK\.7;^3!K
M$#L.BI(">W8?6OYUF_8#_P""@GWA^S-\1"!UQI%QC_T&O>O^"97['G[9/P\_
M;6\&^-/B-\"/&.EZ'933&^U#5M)F6"%3#(`&8C'WMO7-:4<TQ%2I:5)I'FYE
MP+EF7X">(IYA";CT35_S/W$R#5>_U*PTU!-?7*1+@D,YP..M3K]T9]*^0/\`
M@N4UU!_P3Y\4WMI)L>*YL_G`Y`-Q&"`1R,C(KUJLU3I.?8^"P&$>.QE/#IV<
MFE]Y]4?\)AX8G?9'KEH2#C!F`_K5U+N$LH2,$,,A@*_EB_M[65/_`"&+PD<9
M%R1_*OVH_P""(W[?,O[1?PE'P2^)&L+/XO\`"=N%6:>8M)?V(&V.;)Y9@0RM
MUZHW\6!Y66YQ3QU5P:MV\S[SBOPWQ_#F7K%PJ\ZZKL??T9&XCOBG5#;.9)'.
MWY>-K`]:FKV3\XM8K7#0Q@%SP.Y%9C>-?"B7<EJWB"V$L;E)(_,&4(SD$=NA
M_*M&]ADE@<1S;&*D*VW.#ZU_-[_P4`US6X?VV/BO!)K5Z\<?CS50(S>.$"":
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MF+]L;]GR'3/%.LC_`(37PK$EGXAB9UW7*\B*[7CE77&>.'1ATKZ]R!P37\U/
M[&'[4?CW]AS]I&P^*.GVER#9SO9>)]%W8-Q;9(FB*G!5E*@C/0Q\]17]%_PQ
M^)W@OXO^!M*^(G@+5XK_`$K5K1+BSN8B</&PR#SR/0@\@@@\BOHLGQGMZ/LJ
MC]];GXGQ[PS#(LS=?#?[O5O*#[=U^)TD^"`:_&;_`(.0`#^TCX&SV\*N?_([
M5^RSLI..^17XT_\`!R!_R<EX'_[%1O\`TH:GG;_X3I'1X6K_`(S*C_AE^1]!
M_P#!M[Q^RGXR/_519O\`T@LZ_10D;]N>HK\Z?^#;X_\`&*WC+_LH<W_I#9U^
MBY568ENP%:91_N<3Q..K?ZUXJ_\`,_R/,OVJ?VC?"?[*/P5USXT^-ILVFDVQ
M:*V#A6N9CQ'"F?XG;`%?SK?'[XY_$K]JKXM:A\6/B+>2ZAK.K7(BM+=%+_9T
MW8CMXE/.Q"<`#DD^M?HC_P`''GQ[N+K7?!7[-NE7[+;P!M:U:->DCMNA@!^G
M[T_C7A__``0V_95L_P!H']J0?$;Q3IHNM#\!P+>2PS1Y6:^<LL(;_=(:;']\
M`]J\;-:\L=C5A(GZ3P'@L#PUPM5SW$1_>-/EOWZ?>?5__!+C_@C3X+\`>%M-
M^/'[4OABVU;Q1>QQW6E>'KZ/?;Z4A&Y#*A!$LX!SD\+G`&<U^C5AHNEZ3IZ6
M.G6,<$,8Q'%$H"J.P`'0"K5G%Y>?H/ZU/7TF&PU/"TE"*V/R'-\YS#/,7*OB
MJC=^E]$5?L=M(C12*'5AAE89!KP[]M']@;]G_P#;)\"OX?\`B+X+M4U6&-O[
M'\0V<"I>6,N`%9)!@D#C*'*D#ITKWNHKDD8(]#6E2C2K0<9JZ9P83$5\!5C4
MH2LT[H_FD_:Z_93^(G['OQGU'X4?$"RWO$OF:5J,$96+4;7(VS*3W7."ISM8
M$=1FOT\_X(8_\%"M4^-OA"?]F'XOZY)>>(_#UK]HT/4+B7,E_8C"&-L\M)&<
M$GNLBYY!SZ-_P6\_90L?V@/V4;[Q[I&CH_B'P0&U*QN`GS/;`#SX21R5*@-]
M8Q7X[_L=?'#4?V=OVF_!?QAT^[=/[(UJ$705MHEM7)BEC8#@YC=QGWKY50>4
M9@HI^Y(_?/;4?$#@R<JZ3Q%'JM]%I]Y^C/\`P<N_LIMXZ^"GA?\`:=\*Z-YN
MH>#;J33];:,'+V-R4\MFYY,<JA5]YSGH*_$ZXMM@RIQ[BOZO?B?\/_!O[1/P
M>U;X;^*[-;S1?%.C2VMW$QX:*6,C<O<,-P*GL0I[5_,1^UG^S;XT_9+_`&@_
M$O[/OCM#]JT"^*V]TR[5O+9@'AG7/9XV4^QW`X*D#]1RG$J4?9G\.>(635<-
MC5C8K=^]IM;3]#S.GQJQ0NAP58$$=B#D?RIE/B(`;-?0-I:GYC=K8_2O_@W)
M_;%G^$_QVU#]E?QEJ[#1?',+7.A!Y.+?4X@H*Y;H)8L@8_B11C+5^ZV1ZBOY
M'_A/\2?$7P;^)>@_%7PG<B'5/#NJ6]]9,6/^LBE$@''\)`9&'<-7]5'P1^)>
MA_&KX6^'?BSX78-IWB+1X-0L3NY\N6)9`#[@LP_"OE<WH*-7VBZG[7P!FCKX
M&6'F[RCJO\CLYY-K`>H.*_)7_@XT_:,GO-<\*?LPZ/J),,.-;UBWC8?,Q62.
M%6[\`R-CU(/4`C]6?$6HV6BZ0^JZF^R&VB>220C[@522WM@`U_-_^V/\8M7_
M`&N/VO?%?Q%TN.:ZEUSQ"+31+>-<EK='6"VC0>K(J'\SV-?%9[B)0PGLX;R/
MZ-\+\I6/SUXNJOW=&/,[[7/T`_X-SOV:([;P[XJ_:GUK3MHN[HZ)X?:099HD
MVR7#@^F]E3ZQFOT*_:C^/_@W]F'X'^(?C9XWO#%9:)I\DZQJ?GGDP=D2`]79
ML*!ZD5E?L<_`2V_9B_9T\*?!BQ@7&DZ:D=[)&`!+<L`TLGXN6-?G[_P<<_M`
MWT$/@?\`9KT*Y:..83ZUK<8;J1B.U!_V0WG,1URJUHY/+,J4E\21P\D^->.)
M4U\,I_=%:_H?G9^TM^T/\1_VJ/B_JOQ:^)NIF[O=2FVP6@;=#:0#`2"-<8"J
M!CIR2Q.2Q)_3O_@EK_P1I\)>!]+T[XZ_M8^%8=4\0W'[_2O#%ZI>WTU"ORM-
M&1B2;D\-E4(!QN'R_*?_``1"_92TW]H7]K3_`(3;Q1IJ3:#X%MUU*9)4W":]
M:0"V7GC@JSG'=/<5^\R(%4+C@5PY1@8XC_:JVLGL?9^)'$U3+9+(\LER4XI<
MS6FI0T[1=)TFT2RT_3X;:%%`CAAC"JH`P``.@]JG^S6I<.5!(Z$CI5FBOI.5
M7/Q'WGJW=G@W[8G["G[/?[87@.X\.?$WP5`=0\EAI>OVZ[;NS<\@H_IVVG*X
M)XK\&OVQ?V1_B-^QK\8KKX6^/87DA7<^AZLL;)'J%J#A9ESRK<_,O5#QG(S7
M]+K`E?EZ]J^-/^"V/[)%E^T?^R5J/C#3],637?`5M<ZSIT@`WO"J`W,0]=T2
M%@.[Q)UQ7E9IE]'$4_:)6DNQ^@\"<7X[(\>L-4GS4*CLT];7/'?^"%7_``4*
MUSXN^')OV4OBSX@:ZUOP[8^=X;O+E_WEY8J?FBSU=XLK[[&7.2*_2ZOYBOV5
MOC;J?[.?[0/A7XT:5=R1_P!C:Q#<7JQC)D@9]L\8_P!Z-B![*1W%?TS:=JUK
MJ=C#>VTRR+/$'C93D,",Y%3D^,GB*3IR=W$OQ(R&EDV;^VH1M2JJZ]>OYG*?
MM%?&7PQ^S_\`"C6/B]XTU-;72]"T^6ZNF+`%]@R$7/5F.%`[E@*_G9_:_P#V
ML_B9^V=\9[WXL?$"_F,<K^5HFEJ2(K*U!'EHBCN>&+'))8\XK]$_^#C?]HRZ
MTWPGX+_9OT"[=1J\\VK:['&Y4F&(I'`GIAI&E8CK^Y'J,_-/_!#+]DBS_:%_
M:G_X6%XLTM)=#\`01Z@T<JEQ/J#2+Y"\\;5VM(>^8X_>N',\15Q6+6%CMU/K
M.",!A.'.&ZG$.)2<]>2_X?>SZC_X)??\$8/!_A71M-^-O[7OA*'5M=N5$^F>
M%-07?!IH*Y5ID/#S<G@_*N!P6!V_I9HOAK0?#UBFF:'I,%G;QJ!'!;1A%08Z
M`#@#V%:84*,`=*6O>PV$HX6GRTT?DV<YWF6>XR6(Q<VV^G1%86D(X$>WUP<5
M#<Z+I=]9FUO+*.2,C:5<=JOT5NDK:GDJ\97B[,\BM?V+/V8=-^-MC^T+I/P?
MTFR\7V$$T,&KV<9B=Q(NTEU0A78#(#,"1N;!&37J<6(8C'M(VKG![5:P/2BB
M,(QO9;FE>M6Q$E*I)MI65W<KD_)GW7^8K\0?^#@\Y_;4TW_L3[;_`-&RU^WK
M_P"L;ZK_`#K\0?\`@X.Y_;4TT?\`4G6W_HV:O(SM7P27H?H7A9*,.+8.7\K/
ML;_@WE@CD_8?U$L@&/'M\=WOY%M_@*^^?*@_NC\J^!_^#>9T3]AK427`_P"*
M]OB1G_IWMZ^^MT`&1M_*N_`7EA(W['RO%C3XFQ7+I[[_`#&BWB8@@X`ZC'6F
M-:V[,=L*G=][MG_.*E6XB0X+*`>].9]V'09!Z&NKJ?/KW%?N2#I7R%_P7+D"
M_P#!.KQA'GEKBR_]*8Z^O:^/_P#@N?\`\H[/%W_7Q9?^E,=<^+_W:?H>]PY%
M3S[#1?\`/'\S\:OV&_V=+?\`:H_:#@^!]Q-Y<NL:+JAL9W)"PW,5C-+"_P`I
M!.)%3(.1ANE9_P`&OBC\7/V)OVD[3QCIMI/I/B#PIJK0:GI]PV`Z_=FMI`.-
MK(2.F1P1@@$>T_\`!#[!_P""DG@T#_GQU/\`](I:^E?^"]G[!,TT0_;-^'NB
M;!"D5MXTM[8`;UW;(KX@=QOV.?[NTX`0FOD<-AJE3`QK4='%L_H',\_I4>+9
MY1CG>A6BK7Z/5'Z1?LN_'_P9^TQ\'='^,?@6_$NGZQ813+&S#S+=R/GAD'\+
MHV58=B*]%!!&0:_#;_@B-^WJ/V>_B_\`\,\^/]4">$O&MU''8FY;"Z?J!)"@
M?W5DW%6ST(7.,&OVZL9;<VH:$;E;)#8ZGO7U.`Q4<70YENC\)XLR&IP[FLJ#
M^!N\7W3+$_$1^AK^:_\`X*$\?MO_`!='_4^:O_Z.>OZ4)_\`4GZ5_-A_P4)_
MY/@^+G_8^ZO_`.CGKS,^_AP]5^9]MX0ZYMB%_P!.S]-OV9/^3;?A[_V(^D_^
MD<5%2?LQ?\FU_#S_`+$;2?\`TCBHKK6QY567[V7JS\>O!0_XK/2!_P!12W_]
M&+7]07A>W^T^#;!&;@V,088Z@H,C\J_E^\#_`/(ZZ/\`]A6W_P#1JU_4+X*.
M?"M@A_Y\XL?]\"O.X<;E2FV?2^,S_?X677E9^.__``7:_8*7X1_$`?M5?#C3
M2-"\2W*KXF@MHPJ65^1M\\@=$E4-N_V\G^+C6_X(/_\`!0!_`WB\?L@?$[55
M_L[5YWG\)W%U/_J+DJ2]JA(QL;864<89B.=W'ZJ_&WX*>`OCU\.]6^%GQ&TI
M;W3=7LGMKB%C_"V""/<$`@]OQ-?SM?M2?L\_$O\`8<_:1U#X<ZS<7$&H:#?)
M>:'K$49C%S#NW074?<#Y<''\:N.F*>84IY=CEBX+W>I'">-P_&/#TLBQ;_?1
M5X-]?^&T/Z4+>=;D>8%&.""#U'-?C?\`\'('_)R7@8YZ^%'_`/2AJ^^?^"6/
M[;6G?MH?L\P:WJM_"/%.@+%8^*;-6`9)PI"2[>H215WCW+>E?`O_``<A'/[2
M'@7:?^97;_T>U=>;5*=?*G.&J9XWAU@L3EW'D<-65I04T_N/H/\`X-OE_P",
M5?&9_P"JB3#_`,D;.OT5D&3G/45^=?\`P;?_`/)JOC/_`+*+-_Z06=?HJW/Z
M?SK;*E_L,3YGCG7BG%_XOT/P/_X+J>)+K6_^"BOBO3)KG>NDZ;I5G&@;.P&R
M6<`^G,\A_$5]M_\`!N5X,M-._9/\4^+XPBW6J>/+B">0)R\,-K;&,$YZ@RR'
M_@5?%_\`P7C\*W/A_P#X*&ZWK.`!K>A:==H0@Y"VYMN?7F(5]@?\&W/Q#L]5
M_9\\:_#1[M/M6D>,#?>6#UAN;:)5/YP/^=>5A(0_MR4GN?I/$,:L_"O#>S>B
M<;GZ2VRE4&6[8Z5+3(?Z"GU]2?AK=V%,FC\SOC@T^HYG*E0.]%KBD[*YC^,?
M"FF>*_#&H^'=802VE]8RV]S$PR'C=&1@?JK$?C7\N.JZ<NF:K/IK2^8L%R\3
M-C&X*Y4GVX%?U"?$_P`;:9\//`>M^-M;G"6>D:9/>7+9'"11%R/TK^7>ZFN]
M7U9[J67#W,I;9@<LS$G]2:^8XE2_=/JG_D?MG@^I^SQDG\-E]_O']*_[%>MW
M?C']DKX;>+=3E$EQJO@'2+J=RO)D>RB=B?7):ODC_@NO_P`$UY_VL?A3%\=?
MA+HAN/'WA"V;%K;Q_/JMB`6>`=S(IPR=>K#C.:^QOV2_"DO@7]FCP!X)G4*V
MC^#-,LBH[>5:QQ_^RUW\EK#.I2;O^E?586K.DHS3ULC\-XAP%#-'B*$]G)_F
M?R%FQDC9XIB5DC8K)&1RC`X(/I4()0D$5^KO_!;G_@C[=^&+_4/VROV8?#$S
M:9(GF>-O#.GP;FM\')O85'.W!'F)CY=I88`(K\IK@JP5U7&[)QR>.,<D?_JK
M[3"XE8J-T?S=G.38K)L6Z51:=!/.!P#&/SK^@?\`X-WOC?+\5?\`@GS8^$[^
M^\^_\#>([S1959OF6#"7$!QV&R?8/^N9^@_GT'45^K/_``;`_%N;2OBI\3O@
MQ/>A%U32+35;:`GEG@D>-L#UVS+D]^/05R9O24L-=;H]W@+%?5<\2Z23/OG_
M`(+*_M%K^S[^Q)XC73K_`,C5_%D1T#2V1L.IN5*2LN.XBWX/8D5^7/\`P1,_
M9X'QS_;4TC6-8T83:+X&M3K=Y(02AF4K';H?]K>V[_=1J])_X."_VBY?B%^T
M7HGP)TS5!)9>"[*2:]1)1M-Y<E2RMC^Y"JX/4;LC!YKZU_X(*?LZ?\*G_9*_
MX6QK>G^3JGCR[-T"W#)9PLT4(/\`OX>0?[+BOS*<5CLTBEM`_M^A_P`8KX<R
MJ;5<4[>?+V^X^\)8R5(#``K\HQT-?@W_`,%U==N=8_;_`-7MKB=F%CH5C!&A
M/"C:S\?BQK]YI&`5]WW0.N.E?A/_`,%Z_"]WH?[>=WK,BC[/J_ARRN+9MN,A
M0T;?7E?UK?/_`/<3QO"F4%Q4HRW<;'UW_P`&YO@2RL_V;?%OCI#B?4_%I@D)
M&?DAACVC_P`B/7Z2D'&`<5^8_P#P;C?$JUO/@KXW^%TETAN-.\11WL4.>?+G
MA"Y_.%C^%?IQD=,UU94_]@@?/<;PJ4^*\5">ZD%%%%>@?*A6%\1]*M=<\':E
MH]ZH:*ZL)H9`1D%60J>._!-;M<S\7O%&F^"_AYK/BO5[A(K73=(NKNX>1L!8
MXXB[$^P`J*G\-FM!2=>'+O=?F?S!^--&M/#GC+5_#UB28;'5;FWC+=2$E90?
MTK^D']BC7KOQ?^R9\.O$=Y<%WN?!VG.[GJQ^S1J23[E2WX^U?S>>+=9C\1^*
M]3\0HH47^H37(4'IYCL_'YU_2=^R9X3N_`/[,?@'P;?0>5/IWA'3X)XQGB18
M%##\Z^:R&*6+J-'[9XM17]CX!3^)I?\`I*O^A^.O_!>[7KW4OV^+O1IY-T.F
M>&;&*W![!O,<_JU?87_!N7X5T^Q_9@\6>++?B[U+Q<8)FV_P0PQ[1_Y$:OD_
M_@X%\'W6B_MQP>+&C80:]X1LIH21P?++QM^H'YU])_\`!M[\3;/4OA/XZ^$L
MMTGVC2]:BU&*(?>V31A2?SB`J,-_R/))FF>P=7PIP]6EM[M_Z]3].Z***^K/
MPH*8TI`!"]:?6;XCOY=-T&YOH)-KPPED8C(!QZ>E*^HXQ<I**W;L:._CGTIO
MFC&<5^&]Y_P7D_;[MO&KZ5_:?A3RDU1K<J/#9;:GFE.<2Y!Q@Y/KTK]L?!&M
M3^(O!^FZU>,#-=6,<LQ48&\J"<#L,YKFPN+IXIRY>A[N=\.9IP_&G+&0LJBN
MC1?[S'W7^=?B%_P<'C'[:FFG_J3K;_T;+7[>OU?ZK_.OQ"_X.$/^3U-,_P"Q
M.MO_`$;+7GYW=X'3^MCZ7PO:7%M/TZ'`?L3?\%:OB]^P]\)9OA)X#^&OA[5K
M2;69M1:ZU2:X$@>1(T*XC<#`$?Z^W/L7_$1O^TW_`-$4\&_]_P"\_P#CM=A_
MP1R_X)U?LC_M7?LM7GQ$^-_PT.K:S#XLNK-;H:K=0_N4B@95VQ2*O!=CG&>>
MM?7'_#D7_@G-_P!$+;_P?W__`,>KEP^'S=T(^SJ)+S1]=GN=>']#.*\,5@Y2
MJ*3N[O\`S/A4_P#!QI^TRQWM\$O!IV*2/W]YP?\`O[7ZG_L;_&[7/VAOV9?!
MWQL\2:7;65[XBT6*]NK2T9C'"SY.%+$DCZUXQ+_P1&_X)S@9'P/9?7_B?W_(
M]/\`75](_"KX7>#O@KX"TKX6_#S118:!H=DMMIUGYSR>5$O1=SDLV/4DFO4P
M5',(/_:)J2\C\^XHS3A;&481RO#NF[Z[_JV=9UKX^_X+G_\`*.SQ</\`IXLO
M_2F.OL$8QQ7Q]_P7/_Y1V^+O^OBR_P#2F.NG%?[M/T9Y?#/_`"4&%_QQ_,_,
M/_@A\<?\%)O!I_Z<=3_](I:_=SXA>$/#WCKPAJ7@_P`3Z5%>6&IV3VMW;2Q[
MEE1QM*D'C!!Q7X1_\$/S_P`;)?!O'_+CJ?\`Z12U^^KQQ[?GR?>O*X?2E@&G
MW9]EXK2G#BE2@[-1C^;/YR?^"@G[(OB3]BG]HJ]\!"*Y.@W<C7_A34V./.MM
MQ'WO^>L>5!P<@D-WQ7ZN_P#!''_@H(W[4_P+C^'?C>]CD\;^$+9(-2)?#7MO
MNVQW2J>3P55CS\V#GY@*[[_@J?\`L0Z3^V;^SG>:+H]G"/%6@1S:AX5N)(P2
M;E5!\@GJ$EVA#[[3VK\0/V9?VB/B3^Q%^T99?$W1(+JWOM%O7L];TE_D:>`-
MB:W;CDDJ`!TW(#U`KAGSY/B[Q^"70^DH>R\1.%72;_VJ@M/-?\,?TM2MFW+>
MU?S8_P#!0H#_`(;A^+H'3_A/M7Q_W^>OZ&_@I\9O"'QZ^&>E?$_P)J\=YI>K
M6B3VLJ,#\K#H<=&!R"/:OYY/^"A*[?VX_B\GIX^U@#_O\]=6>ZX>G+S7YGE^
M$U*I0SO%TZFDHTV?IQ^S&^/V;/AZ,?\`,CZ3_P"D<5%-_9D_Y-M^'O\`V(^D
M_P#I'%17<HJQY%5+VLO5GX_>"_\`D<=(_P"PK;_^C5K^HGP)_P`BII_'_+G%
M_P"@"OY=_!`#>,](4G'_`!-+?_T8M?U$>`]P\*V".,,+*+(_X`*\SAQKV<T?
M2>,;7M\(KZJ+-BOA_P#X++_L#7/[5/P0E^(W@/2U;QGX0M6FTX``&]MLAI;8
MXYY&YE_VA[U]P54O;6+[*[7$F4"?/NZ8KW\10AB:+ISV9^1Y9F>*RC'T\5AW
M:47^'4_G-_X)Y?M@^(OV)/VC]-^(-PUU_8EW*EAXPTT-S-;,Q5F"GK+$VYN>
M?W;`<G%?1/\`P<#>*_#/CCXQ_#GQIX2U6*]T[4O!1NK.Y@Y22)I&*M^(_6LS
M_@MG^P._[.'QA'Q\^'^F`^%/&MU+)=)''B+3M3#>8X(_A23<SKZE67C.:^._
M'/Q7\4^//!GA3P/K\I>#P=:7%II+L^YEMY9_/6(^H1BX'L0.W/Q>)K5L)2J8
M.2]/,_I+*</@^(,VPG$."TDERU%W6S;^9^M__!M]S^RMXR'_`%4.;_TALZ_1
M<G#X'<5^=/\`P;?+G]E3QF<]/B'/_P"D%G7Z+JIDRP.*^HRI..#C<_!^.+3X
MJQ37\Y^7W_!QG^SS?:YX6\)_M)Z!9/(=$D;2=;*1[MEO,1)%(>^!)'L^LJ5\
M<?\`!(3]KS3?V3OVM;"X\87GV7P[XJC.F:S(6.V-W.Z"7GIME)5C_=D)[5^[
MOQA^"_@[XW^`M9^''CZR2[TK6[![2\MW0?<88W`]F4_,#V(![5_.[^V[^Q7\
M1_V)?C%=_#KQE8RW&ESS/-X=UEHCY&HVW(['@CD.F<\\''(\O-J53"8J.,I*
M]MS]'\/,?A.(,CJ<.8N:BW?E;ZW_`,M#^D/0K^SU*V%W83+)"Z*T;IC#*<D$
M8]1S^-7J_''_`();?\%KX_@KX=L?V?\`]J-Y[K0K6-(-"\5KOEDLHE)`CN1\
MS,B@J!(/NA<$=#7ZN_#KXZ_#'XL>&[?Q9\.O&VDZS87*[H[K3KY94(R1U7Z=
M#R*]G"8ZCBZ2DI*Y^89_PSF?#V-G0K0;BG92MHUT9V-07LD*C9*"=RG:`.OM
M56]\1V>FVWVS4)8HH@I:1WD`"@=R:^._V[_^"RG[._[,FB7/ASX?:U8^,/&C
M1R1VVDV%T&@M9,?*UQ,,H@!'*@ECC&!G-;U<11HQYIR2L>;@,KQ^:5U1PU-R
MD^R.`_X+S_M@:+\)O@$/V?/"FKHOBCQF5AO(T8%K32URTC^Q=PB#ZD_PU^97
M_!/+]GK4OVFOVP/!?PRM[-Y+,:HE_K+A,K':6^)I-W8!L*GUD'K7"?%KXL_%
MC]ISXM7GQ$\?7MWK?B;Q%>(#%%$S._\`#$D4?)`12451R!@X;J?V@_X(Z_\`
M!.S4OV/_`(;S>/OBC91)XW\2QYO+<*"-,ML*4M5()&X-N9R..5'\()^7C[7.
M,SYK>Y$_<\4\'X<\&RPBDI8FK&[?6[W7R/M70K(V$36Z*!$BJL:J>@`Q^%7R
M,C%16\?EDC=V'%2U]=9+1'\^)R:O+=Z_>4M2M(=1L)+&XA62.9-LD<B@@@]0
M0>V*_%C_`(+/?\$6[[X57&I?M:?LJ^'"^@SO+=^+_#%JNY],8G<]W;+SF(Y8
MM&,[>"HP3C]L3$>S8_"JNIZ9;ZE$;2]1)(G0JZ.F0P/4$'MCC\:Z,+BJF$G=
M;'BYSDF$SG#\E5>\MF?R(2)%<J&0`#`/#<8_PK[`_P""'_QNT;X'?MZV'B77
MKQ8["]\&ZW'<R,,!1#9RWI'/3(M%_/'6O:O^"YO_``25L?V>?$%S^UA^SKHF
MSP?J=V#XJT6TC"C1+B0?\?$>,%8)&!##D(\@Z*>/SC\(:A>:=K=G=6EQ)`Q9
MX6DC?:2DB%&!/8%6(/L37T&(Q'M<MG..ME=GY+DN2U,MXSPN$KNT95(QOY-G
MTE96_C3]N_\`;.5Y3++JGQ'\<;CA>(89YMQ8CLD<9P?]F,BOZ-/A1X)T/X:_
M#G1O`&@6?V:QT;38K2TA'\,<:[%_,`'\:_(C_@WA_9I;QU\;?$O[1FK6F;/P
MA9QV6EN\>0UY<AG?'^Y&.1V\X<\5^R=O:J8E\N8D;<`XZBOSS(Z-J,JLOM-_
MF?V#XFYFJF94\MI.\*$$OG9?H3SH9K9HU&2PQ_\`7K\R?^#BW]G#4O$OPW\(
M_M(:!IK22>&9)=.UUD3</LLS*T3MZ!)L\]O-R>`:_3I5V@#/2N6^,GPN\+?&
M+X<ZO\-?&NFK>:7K.G36E[`ZY#1NN#^/<'L17I8RA'$X>5-]3XOAW-)Y)F]'
M&+[+U^>C_,_!#_@E!^UQ:_L@?M:Z=KOBO5?L_AKQ+!_8WB#<^$CC=PT<[9Z;
M)$3GLK2Y^\*_H,M-3L]0B2YLYDEC<`JZ'((_K7\X/[='[%WQ'_8<^,EU\/\`
MQ7833:%<R[_#>MF/]UJ$)`PI8YQ(HX9.ORDC.:^L/^"7/_!9]?@;IEA\"?VH
MY)[KP[:*(=+\4;C)/I\0&U8YDY:2,'`5UR5!Y!QFOG\MQLL)-X>KI;8_6^.^
M'(<2TEG>5>_=+F2W?_#'[,QGDBG5QOPV^.OPN^+N@P>*?AEXRT_6M/N(U9+J
MQNA(N",C.W.T^S8/'2NBN?$-G:PFXDFBVCJ1)G'UQTKZ=3@U=-?>?B%2C6I3
MY)P:?:S+4LJPC)%?`W_!=G]M;1/@_P#L\CX`>$];4^)/'D3V]PEL06M=.!7S
MG?\`NK)D1XZL"^,[3CK_`-NS_@L5^SK^R[X>O?#'A+6;+Q?XR:(I#HFCWH>.
M!B<!IYAE(QU.,[N.G-?B=\7?BS\5?VH/B]>?$3QM>W6LZ]K]\%@A@0M]XD1P
MPH.0H)VA1G)Y[UXF:9BJ,73IN[9^G\`\%8C'8N&8X^/)0AKKI>WJ=1^PC^SK
M>_M0?M5>%?A186,DUK/J"76L*R[MEA`ZO-G_`&2G[LGU<#N*_I2AM62%(F`^
M50/7I7PU_P`$:?\`@G7=?LI?"QOBO\2;/R?'7BF!?MUNZ9;3K,-N2U![%B%=
MQW;`(^0&ONL#!SFNC*<-[##\SWEN>7XB<1QS_.N6D[TZ7NQ_4_.S_@X0_9<U
M'XF?L^Z-\??#&E-+>^`);C^TC'G<=.G5!(YQU\MXXW!/0;O4U^;7_!-G]L:X
M_8Q_:AT[XC3S7']AZI&=-\36R*6S9O(A+JO]Y&4.,<X5@/OU_1!XW\':5XZ\
M.77A/7K:*XL+^UEM[VWFB#I-$ZE71@>"""017X%?\%.O^"</C7]B#XHW&JZ)
M87%]\/\`5+G.@:P1G[,S#=]DF;)VLOS89L!E7/7(''FN'JT:RQ-%7?4^EX`S
MG!9EE57A_'OW9?#?[S]]_"_C#PYXTT>U\0>&-7@OK.\@2:UN;:0.DD;#*L".
M"".<UJ1D;BO<=:_!7_@F]_P5P^(?[%\\'P\^(&FR>)?`A<F.S\XBYTHD'FW+
M':8^F8SCN0PY!_7W]GO_`(*&?LG?M+Z+!J_PO^+^DS7$RJ9M+O+@6UW"Q'W&
MBEVL3U&5!4XX)KT,%F%'%T[WU/B>(N#<VX?Q#4H.5-[26J_#8]PK)\5#=X>O
MO^O-_P"568->L+N`3VLRNI&>#C^E<[\1O'?AKPUX4O;W6]8M+6+[*P\VXNXT
M7D8SDL*[95*:IR=^A\Q0I598F$5%WNNA_,IJ"E?B)/[ZZ?\`T<*_IZ^&O_(@
MZ*/^H3!_Z`*_F%NW2?X@S.C9']L@E@01DR+D#Z'C/>OZ>/AHV?`.B$=]*@_]
M`%>!D/O5:K7<_7_%Z,HX?+[_`,G^1LOT;_>'\Z_$+_@X0_Y/4TS_`+$ZV_\`
M1LM?M[)PC-[K_.OQ"_X.$/\`D]33/^Q-MO\`T;+77G&F#1\WX7R4>+(-_P`K
M_(^R/^#>'_DQ_4".WCV^_P#2>WK[^K\\/^#?7Q9H&B?L4ZA9:KK%I;2MXYO7
M1+FX5"R^1;\C/;@_B#7WD/B5X([^*M-_\&$7_P`575@:E-82*;1X'%=*L^),
M4^5_$^C[F[16"WQ*\$=$\4:<3Z?VA%_\52)\1_"UQ<BTL]?TZ61L;8TOXRS'
M(X`!))YX%=:J4V[)K[SY_P!E5_E?W,WZ^/O^"Y_/_!.WQ=_U\67_`*4QU]@]
M:^0/^"YR_P#&NKQ?)_=N++C_`+>8ZRQ37U:?HSV.&G;B#"O^_'\S\PO^"'YS
M_P`%(_!G_7CJG_I%+7[]CD#-?@'_`,$/,O\`\%(O!N!TLM4'_DC,?Z5^_HZ5
MY>0*V!MYL^R\5VGQ/I_(OU*VH1228"*"`K9XZ>GZU^//_!>C]@J7P-XK'[8O
MPQT9ETO6)H[;Q;:P)\L-T5_=W(4<*'V[6/3<<GK7[&2QM)]U\<$5S7Q0^$GA
M'XP>`M4^&_CS3H[[2=8LWMM0MIDR)$92I^A`.0>Q`-=^/P<,;A94WN?(\,Y_
MB>'<WABZ>L5I*/='X_\`_!"W]O>U^#GQ%;]EKXE:OC0?$MRS^'KB5LQV=^5)
M:+)Y42X``/&Y5[L:^4/^"@LB3?MO?%N5&&'\>:N0N><>?)@X]#1^V+^S/X]_
M8G_:1U'X7ZM-<1OIUV+WP[JN=IN;3S0T,Z'^\&7!]&5A_#7GWQ3\?:G\4_'^
MM?$?6X$CO=;O)[R\6,Y!E<$L>>>3S^-?&5<555*&#J+6#1_2&3Y/A:F:U,[P
M37LZ]-W2[GZ\?LR?\FV_#W_L1])_](XJ*/V9"/\`AFWX>\_\R/I/_I'%17UT
M?A1^,U4_:R]6?G/X-_X)V_MNVOC'2KF[_9A\9QQ1:E`\KR:0RJJB126)]`.:
M_H?\"V]S:>'+2UO3^^BM8DE&,;6"@$?45KB-!SM%.'TJL#EU'`7Y-V>#Q1Q=
MF'%4Z<\5&*<>R"D=$=#&Z@J1@@TM%>@?*'FW[4W[/?@;]I;X,ZW\(/'6G^=9
M:OITT(<<O;RE?DE3/1E;!'OQT)%?S[_&#]@O]JOX1_$S6_AQ=?`SQ9JITB^:
M!-4TCP[=3VUVG598Y$C*L&4@\'@DCJ*_I1J.2VBD.6B0_45YV.RVEC6FW9H^
MTX2XVS'A1U(TES0GO%NWZ,_/_P#X-\/A[\0OAQ^S+XLTCXA>"-9T.ZG\>S2I
M:ZSIDMK(\9L;4!PLB@[21C\*_0&'[O2A((H^(T`'H!3ZZ\/15"DH)['SN<9C
M+-LRJ8MQY>=WMO8*\S_:4_9>^#?[4?P[N/AS\7_"<&I6DP!@D(*S6\@P5DCD
M7YD88ZCJ,@Y!(KTRBM)14U:6J.&C7K8:JJM*3C);-'XB_M5?\$"?V@_A;J=U
MK_[.=['XVT4R/+%9F407]NN?]7M8A)C@D;@RGCE>17RCJ?PS_:Y_9UU42S^!
M?B!X.NH),I<+97MJQVC&%E10#TZY/U-?TSE0W!%1M:PL<F%3_P`!%>-6R+#5
M'>FW'T/TO`>*.;T:"HXVE&O%=U9_?9G\S>H?$[]L3XM.?#VO>.?B1XD:7$;6
MT^IWMT7]%VL6+<]N:]-^`G_!)/\`;G^/E_`(OA!J'AFPEE'F:IXOMVM(XP3]
M\1MB60]P`B_6OZ%Q:VHY^S(/?:*>B1K]Q0/H*RAD-.3_`'TW+\#JJ^*^,I4>
M3`86%%]UJ_R1\:?L`?\`!'OX'_L<S1>/?%$B>+/&;H2VL7EOMCM&)Y\B+)"'
MI\YR_7D9Q7V(EO#$5PN-OW0O0?\`UO:K-&!Z5[5"A2PT.6FK'YGF.8XW-L4\
M1BIN4GW&1$%V.#FGT45L<*OU"FR@8IU%#U&8'C?P%X/^(_AC4/!GC?P];:GI
M>JVCVVH6-W'NCGB9<,K#W'\AZ"OYFOVY?V/_`!)^QC^UAKGP.DTZ]GTVWNQ>
M>';R2$L;G3Y6_=/N'#$$,C8_BC<=J_J$K%U/P+X8UJZ2^U?P[8W<T8`66ZM(
MW90#D`%E)`!YZUO1Q$Z4)P>JDK'D9AE%''XJAB&[3I24D_1IV_`^?_\`@DU^
MS8/V:_V+_"_AG5;'R-8UBT36-:3;AH[BX42&-CU)0;4_X#7TP%7`VC&.E-@M
MX[<;8T"C:``HP`!^E25S0A&G%1BM$>_B\35QF)E7J.[D[A45P@DPA8C@]#4M
M%4CF:NK'F'[1G[,_PA_:?^'UQ\.?C%X4M]4L)GS&\HQ+;R8XDC<?-&XSU!%?
MDU^UC_P0.^/_`,-+NY\0_LZ:I!XVT/K;Z;,1;W]NN?NX/[N<#KD,I_V:_;2D
M*J1@@8KBQ&7X3$ZSCKW/I.'^*\[X;FOJE3W>SU1_,QJGPI_;!_9TU/S+KP%X
M_P#!TT1^:[BL[RT!9>X:,!6QG@ACU]Z74?BC^V-\5T7PYJOQ!^)'B,,/EL[C
M4;Z\WCV3<W'UK^F-K:V/WX%/U44GV6S_`.?9/^^17F/(FG[M5I?UYGW7_$5%
M/WJN`IREU??\#^>#X$?\$H/VY/CYJ$$>F_!O4/#-C+(%?4?%MLUC'$IZML;;
M(YQQQ&"217ZF?\$__P#@CE\$OV2;F/Q]XVF3QAXU3:T.LWUIMCL&P0?LT9)V
M'G`<_/@<;<MG[75$7[J`?04M=F'RC"4-6KONSYK/?$#/\\INDY*%/^6)!;VU
MO;1".`;5'``Z?E4_2BBO3C%15D?#W;>HV3&0:YOXD_"GX=?%SPK=^"OB/X3L
MM8TR^C*7=E?0B1)![@]QP01R"`1S7344G%2T94)SI34H.S74_(O]KO\`X-[_
M`!#9WESXR_9#\8136S?O/^$7UN8J\1SR(K@@[AC^%P#Q]ZOA;XD_L6_MA?!&
M_E?QY\`O&&GFW8@:A#H\TUNI_O":$.I'_`OP%?TNX'3%->*)_OQ!OJ*\G$9)
MA*KYH>Z^Z/TC*/%'/\OHJCB%&M#M)'\QFD_%K]J3PY:C3='^(_CZQC0;?)AU
M>]C"^N!N&.:U;#X._MD?&B8QVOPQ^)/B8L=I^T:9?W<:G_>9"J_F/J*_I;-I
M:DY-JG_?(I5MX0<^2@^@K".223LZK:_KS/0GXI1M>E@*<9=]_P!#\&O@%_P1
M'_;M^*6L6-]XO\*67@[3@Z.USKMVIE`W9P((BYS]6'45^Z/@O2I-#\*:?HT\
M@D>SM5@=U7`8H-N0,G@XK7"*.BTM>GA,%1P<7[/=GQ'$G$^9\45XU,6U[NR6
MR*TI/EG`].OU%?D/_P`%O?V2OVD?C=^UE8>*_A+\%_$/B'38?"T%N]]I5B98
MQ(LDA*G'0C(K]@::T:-U4?E58K"PQ=+DEL<_#N>8CAS,UC:"3DE97V/YP++]
M@']O[3H?*T_]G+Q[!&7W;(=.D52V",X!QG!Q4G_#`_\`P42_Z-Z^(G_@'/\`
MXU_1T(8\8VC\J=L3^Z/RKSO[$I6MS,^YGXK9K4FYRP]-M^1_.&/V"/\`@HCG
M`_9Z^(F3_P!.<_\`C7H'[*_[%/[>/AC]H_P+X@\4?`OQY!I]EXNL)M0FN[:5
M(X84F4L[DGE0"3@^M?OYM7^Z/RH"J.0HS]*=/):,)\W,SEQ?B7F&,P\Z4L/3
M7,K:)B1;O+7=UQS7R]_P6&^%WQ`^,7[#/B;P)\,_#%]K.K74UJ;?3M.BWS2[
M9T)(!],5]1TA4-PPS7K5*<:E-P>S/@<!C*F7XVGB8*[@T]?(_$__`()"?L7_
M`+5?PH_;L\+>/_B5\"?$/A_1[.WU`W.I:E8&*./?93(J%B2"2S?I7[8CD9I!
M'&#D(/RI:PP>#I8*ER0/2XBX@Q7$F/\`K5>*3LEIY!1THHKK/!/C?_@KW^P?
MI_[7?[/5SXG\'Z,)/''A6)KWP^PCR]TN1YEJ<`L0R[MH'\6/4U^*<G[)_P"U
M(C%&_9F\?'$;Y)\(WI.-I&,"'&2<<YQS7].;*K#:PX-,-K!G/DK^0KR<;E-'
M%U543LS[SAGC[,N',#+"QCSQ>UW:WX,_//\`9Q\#>.=,_9Y\!Z;JO@S4[6ZM
M_!FEQ7-M-8S*\,BVD09&!3@@@@CVHK]#?(C_`.>:T5V+#V6YXLN(:LI-\N_G
M_P``?11174?.A1110`4'/8T44`%%%%`!1110`4'/8T44`%&`.@HHH`****`"
MBBB@`HHHH`***3<OJ*`%HI-R_P!X?G2Y![T`%%(&4C(8$#KS070=6'YT`+10
M"",@T9'7(H`,9ZT8'H*,CUI-RGHP_.@!:*3<O]X?G1N7.,B@!:*3<IZ,/SH#
MH1D,/SH`4G!Q14<LP4A4(^8'!S]/\:YKPW\7OAQXT\4:UX(\(^.],U+6/#LB
M1:[IEE>(\]@[J&02H,LA*LK#(Y!!H%=7L=311D>M(64=6'YT#%HI`RGH11N4
M]"*`%Z=336=AP!S7#?%']H/X:?"KQYX/^%_BOQ&MKKOCNZN[?PO8^6S->RVT
M0FE4$`@;4(//K796SF2!2\VXG^+UJDNIE[:/.X+5HLT4A91U8?G1O3&=PQZY
MJ346BD#*>C#\Z-Z8SN'YT`+12!E/1A^=&Y<9W#'UH`6BDWH>CC\Z-Z9QN'YT
M`+12;E_O#\ZR?'7CCPK\.O!^I>._&?B*STK2-(M7NM3U.^N%C@M84&7DD=CA
M55<DD]!0)M(UZ*R/!7BK1O&WANR\8>'-=M=1TS5+.*[TN^LYA)%<VTB[XID8
M<,KHRL".""*UBZ#JP_.@=Q#(<<+0C,V<C%<[\2/B+X:^%?@/5OB1XVU5;'1]
M#L7O-4O&1F$$$8W.Y"@DX`)Z4[X6_$+PS\5/`>D?$OP9K27^B^(=*M=2T>]4
M8%Q;3PK+%(`><,CJ>?6G;0RC6C*5D=%11UZ44C4****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****``G`S7FW[5OQ9U?X$_LZ>-OC-H6E6
M]]>>&O#EUJ5M9W3E8IVAC+A&*@D`XQD#//%>DDX&:\7_`&^O#^K>,?V+?B;X
M;T31YKZ[OO!.HPVMG;1EY)I&@8*B@<DD\"KI_$<V,E4CAI<FY\P^$/\`@I[^
MUSID'PD^+/Q>_9I\.Z7\-?BWKVGZ/I-W8^())=5M9;P@6\\L6S9Y4A(88.0"
M-V#77?%?]OO]J'Q'\3?B1X:_9(^!_AC7]!^$05/%FI^)==GM)M1NQ`)Y;6QC
MAB<.Z+E29"HW+@9R,^?_`!I^$OQ,U7]@3]COP58_#_5I]2T#Q/\`#>3Q#906
M3F>PCMHK47#2#^'84;=GICWKS7Q7^SY\*O@1^V+\7YOVNOV<?B+XDT+QWXE?
M7?!?B/P1;ZA<P7,=RBF>QEBLG!617WC,@P0N00#7=%4'&[6I\Q4JYG":I\[M
MIJ?2_P`!O^"E;?&SX^^%?`UOX8M[#PIXZ^%!\9>'-7N7Q<&2.=X[JQ<#Y&,>
MS>6X)!SDCFN9_9I_X*RW?QL^%/QP^)_C+X;6NA#X6Z5-K7AZW^U28UG3"MY]
MFF(8*0TCV94@9'S+SS7FW[>/P.\5?"S]G7X)_'C]CK]G_7[6_P#"$%_IEEX-
M%FSWUGI^KZ?-`Z2H22IC+ACR=K`'M7(_M??L8?&7P!=_!WX(_![P%J.I:-\2
M?AIHOPZ^(>J65H673HK&^L9&OK@C&&9))\D]2CU2AAIZ)&=;&9I1::;?+OYW
MT_4_2+]E[XG>,/BO^SAX/^*_Q!\-6^BZQXBT"'4KW2;:1G2T,J^8L>6Y)"LH
M/;.<<8KXQUO_`(*I?M::G\"?%W[;/PQ_9J\-:A\'M"N+RWTR6[\1W$>LWPAE
M,"WX@2(QBV\TC<N\2!%=@IP,_>FG^%].LO!<'A2RC:"UM[!;6**,XV1JH50#
M[`"OR8UCXH?%+]FK_@E5\2/^">OC[]G;QB?&/A_0=7L?[:BT9O[%N-&:220Z
MC]K!V(/(\TA"=Y=57&6%<]",.=QM<]#,\3BZ$(N+LN1M^NECZQUK_@H%\?OB
M!KGP]^$/[,/PH\/ZEX\\7?#2T\:>(3XIU6>WTK0[6>.,JC/`DDDCO(S(H"X`
M`)/S'''>//\`@K)\3O#?[..E?%*R^`T5QXXM_C%%\/O&/@Q-2^2VO"MR2;6?
MCS-S11;=X"CS""/ES7AOB#X`:+X;\=?!G]ICXT?!;Q?XJ^&WB3X!Z#HU_?>#
MOM4EUH=_!;V\D3S0VDBRF-T.,@,!@]#7:?&3X"_#K6/V7?ASJ7[)_P"S1XQT
M'2K_`/:8\.:IJ5AK>FW*7URD,DBRW\D<[,\</)^9N2`#WKHY</\`RGGTL3FD
MZ#DY/9?BD>[_``B_;Q_:!\*_M(W_`.S-^VG\(/#?AW4#X%F\7Z+JOA+6IKZT
M^PPR%)HI6E1&\Y-K$X&"!P37$Z;_`,%3_P!H>/P'H_[7WB/]G[0;?X&:YXC3
M3K6ZCUV=_$$%G)<-`FH2V_E^3Y)9<E1(7`(XXKH?VH/@CXX^)_\`P4L\+R:=
MX=OQHM]\!/$&D7.MQV[-;6]S/-B-'<<*Q5V('<"OF+]E[]GK]F[P/\/-#_9E
M_:G_`&*?BE??$#2-8.FWB65GJ,VEZB/M6([])5E-NL)3:YR01M)P,XJ.3#\M
M^4*N(S2%54U)\J/JC3_V_?VF_B+^WEXR_9#^"_P"T*_TSP1?Z8^L^++_`%AH
MHH=/N+>":0A=OSW&Z8A(QD%5R3UIW[2W[87[=_[-.F^(_CSXJ_9T\$2?"OPO
MJ8BNXH?%<QUV:P,R1"]2(0^0,EP?*,@;@\=*O_L9_#7Q?X7_`&^_VF?$NI>#
MKZRTS5=5\.G1M0N[)TAO%BTN)',3GB0*?EX/!X[5^?GCOX+:YXT_9+\>>$_C
M)^R!\1?&'[2UW?7LVH^(M4TJXGMM/@%R6\^UN`P@6`0*^R*/<Q9P,<TH1IR>
MBL5B,3CZ.'2DVY-MJWE:Q]6?M%_'#]MK5O\`@I)\(=&^#&E^%IM!UCPEJ&H^
M'-'U3Q-=V]OJ-N4MVFN+Q(X2$EB#GRE4LK<[MN!GJ_"W[9WPR^!/BK]I_P"*
MWC#X+Z)H=Q\.-3L$U[4O#Z[;SQ'</9(T8E<]6W/Y:GC@@G'-87Q^U#QO\"?V
MI_V:/VC==^%?BC6?#.B?#V_T37;C0-)>]EL;NXBM1'YL48WKN.<G&/E/3!KA
M?BO^R-\9?VEO#/[9?A+P_P"!]5M+OQ;XIT?4_"'VZW-NFI&VL[>7RXV?`))C
M*'/`8@$YSB^6F]'L<].MF$-8MN5V]?-(]AT#]OS]L#X:^+/AW<_MA_L_^%O#
MOA#XI:I!I^C:EX:\0375WHEU/&9+>"_CEB107PJEHRVW=ZC%8&L?\%%/VZ_%
MOB_XRZ+\#_V9?"&I:9\&O$E[;ZKJ&N^)9H3J-I"C2Q)`JQMFX*([,"0JYC&<
ML0.8^,WQ8^(?_!1[5_@W\"?#'[-_CGPS=>'O&]AX@^(6I>)/#TEE:Z.;*-_,
MA623_6NSEU7`P0%]:](_9)^''C_0]6_;!D\0^!-4LEU_X@:C<:+Y]FRKJ,#:
M<$26`GAPQ&,CO4N-!0YFM3H]MF$L0J<)/EL^C['TS^R3\>=/_:@_9P\'_'S2
M--DLX?%&B1WOV.4@M;NV0\9(X.U@RY]N:^5[']OO]N?XJ_$3XL>`/V?_`-G/
MP??K\(/$<]GJ5_KVOSVJZC$D:R)'`J(S?:'7S#\V$&U<D;A7L7_!)+PGXM\"
M?\$[OA=X4\<^&[O2=6LO#S+?Z=?PF.:"3[1*=KJ>AP17R/\`L^_M<:Q^R_\`
MM%?M26^H?!#QGXGMM2^)4SZ)/X5T-[U9-26V5!:3;,F$LAMR&?"D`\]JQIQC
M-O0Z\;B<33I8=.5F[I_)7_0C_:F_:^UO]HCQM^QC^TO\%OAT^HZUJVN>)$L?
M#%Y>B%4U!K.*V>&63;\L:2,Q9QSM7(SFOIC]EC]L?X]_$?XL_$O]FO\`:$^#
M^C:5X\^'VE6FIP?\(OK$EQI^JV]S&S0;'E17C<L-IR,8)]#7S1\#?V4_C5\)
M=3_8KLO$/@'4GO+#Q5XLUOQ8D%NTB:+]NM%,,<[KD1\,%(_O`@?=KN/CI\./
MVF(?VM/VI_&WP-\*ZI:ZSJ7P=T*V\'ZK%$8X[J[C23='#*QP74%OH371RTI1
M47H>;AZF84Y2KR;=[-KOHCNH?VV?VTOA!\5O`NA?M<_`WP3I7AGXB^(H]#TZ
M3PCXGN+V^TJ]E1C"EPLT4<<BEL`M&Q"@D\D8J+X;?M[_`+4'QI_:H^(7P/\`
MAO\`L_:'+X;^&/BUK+Q1XIO]99-MF8FV>7%M!>Y9HY<JO[M5VG.6%?'V@_!S
MX<Z[XE^`.N?`/]C;XAVGBG0_B'HDWQ+\<^)M!NUE649,T,DLQ)FS(9&+H"BX
M&6[5]H_L$_#_`,9^'/BK^U1?Z_X5O[*+6_BO-=Z//=V;QB\A^QJN^+<!YB[@
M>1D<\43A14;HJAB\TK34+M+5_@>-M_P5[_:\T;]FNT_;;\3?LR>&D^&EIK\N
MD:Z++Q+(VHRRB_:T$UM$Z!#&"%7#DL9-W`0`U[?\$OVU/VI8?VLM'_9C_:S^
M"'AOPZWC+PU=:YX2O/#NO27GDI;X\VVN]Z*!*H.=R%E.>O6OF3Q#\$OC5)_P
M0M@^&D'PKU]_$8^)4ER=#DT]UNC&/%$DN_RR,[/+^<>JX/>OI#]H_P``?%+4
M?^"H7PG\;^"_"UW+:V'PO\3PMJWD'[);7DB)Y"2/T5F(/<<"L^6FUL5"690J
M<RE)VL_\RM\>OVT_VX?V9K6_^.7Q2_9U\#I\+=-\0I8W4-AXNN)-<%C)=BWB
MO!#Y(@((9&\OS-PY&*VOC1^W9\;?$/[0,?[)?[%?PAT;Q+XKL_#D&O\`B?5?
M%>JR66EZ59SL!#&[1(\C3N"K!`I`4Y-?GI\0/@O_`,)I^R?K?A_Q?^Q]\3O$
M?[1;:_\`:/$OBW6-'NIA8!=15EFMYW9HI(O*\M5CC#'[Y[5]9)>>/?\`@G_^
MW1XJ_:5\7?!7Q9XE\`?%;P1H5K<ZKX4TA[^?1=4TZUCMQ!+;1YD"R(I.X#`;
M@T_94K:J[*CF&-E5:;:AUT9Z?\1?VR_VI=)\>>#/V4?`7P<\&W'QFU?PK+KW
MBR'4?$-PFB:'9).\*2>=%$TTOF/'M0>6#ZXKF)/^"IWCA?@=%XKU;X1V%GXS
MT'XT6?P[\<Z%/J+O;6MS)<I%+-;RJNZ1=C;TW`9#<UY/^UKX-T3XC?M=^"OV
MY/BI^S?\1=0^&GB/X<?V+J=CIVGW<>JZ#>PWD\MO+<6MLZS;)4E(P`<9.<8Y
ML_'3X#^"6_83E^)'[&/[*WC73(=-^+>D>)]7\/:S9W":KK26<J;[E(;AFD9F
M7;C=AB%SCBFHPY5H$\5F-6O/EDTHZ)6W1]0_'#]JCXJ^`/VP/"?[*W@#P3HF
MI77BWP'J^MV-]JM])"L=Y:AO)B<(C8B=L*[CYE!!56YKY+_9,^-G[5&I_LZ_
MM0>*_P!H/P)X0\6^#=$\6^*CK=AJVOW-TWVZ*SM"=*CB:%5.GB/;A\A\R-\O
M6N]\%?%KQS^UA_P59^&'QU\-_L^^-]!\$Z+\/M9TZ+7O$^@R62W%PZ[W4H_S
M1@$JJEAASG'3GCOAA<>-O!?P0_;`_9(UWX,^,$\3>)O%'B_Q-H<Z>'9GL;RR
MGL;.*$17`'ER2NR,1$#NQ@TDE&/F35K8K%8KVG,U'7H]=$>O']O#QCX2^$WP
M`^#G[,OP#T?4_B%\4OASINKZ)X8>^-GH_AS3?L,#DRS*&811[]B!$8L(\<<9
M],U3X@_\%#=/^"MI))\#_AZ_Q*N/$OV2\@/BV=-&MM-$#-]O,WE><V'V1^4$
M#$L3C'-?+]MX"^,O[*VM_LN_MEO\(_$'B31?#_[/VE^$?'VCZ#IYEU#1]MI`
MPN/L_P!]U#/*KHHW`QCVJ[^W!\:=4_:GC^%7Q*UGX)?%1?@A;^*;Z'QWHUKH
M=S::A/(ENAM+F:WC(G:V+NPP.I!SVPO9Q;1M#&XF$)NIS<VR7D=?\1_VN/B?
M\6_V<?VD_P!F[]H;P+I'AWQ_X`\!7$VHGPWJ4MWIUY:W-DSQ3P22HDF,-R'4
M$$CBL_X6_MB_&SP%\$?V8_V1?V:OA_X8U3QEXB^`6B:W)?>-=:FLM.M+2+3;
M=`H:WBDD>1FC?Y0O``)X.:\:^$/P,U73=4_:OO?@K^REXA\"^%_%/PFAC\%Z
M'?:4T)NI1;R(2J'+*\A4-Y3-N7<<@<"N]^+F@_`1OV-_@5\,/VF_V7?B?>^)
M=$^#>A'PUXL\#^'KEK_2-22RAC-JL]N=]K.LL:MA_DYYS@UHHTO::ZHY(5<?
M*G*I=IVM_P"37_(^P_#_`,0?VMY-!L7\3?#7P=#J36<1U"&V\3RF..?8/,5"
M8P2H;(!(!Q17YL^#O"7_``<+IX1TI=$U"Y2R&FP"T36FMS>+%Y:[!.>\N,;S
M_>S14<L/([EBZ]OAD?L[1117`?6!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!UJ(V\3Q>6PRO3%%%-;">KL)]AM!\OD@9.>">M*UI:]XA
M[9S111=DN,>Q$NGV:*$6+`'0`GU)_J:!I]L/F6(##$_B22?U)HHIINXDHW>@
MZ*&*)2B,>1T-?&OQ._X)N_M5?&G1;_X6?%W_`(*+:MJOP[U6_+ZGX?M_`EO;
M:C=6ADWBS;4$N,[,[02(02N5/#&BBE&<J<W8PKT:>)BO:'UEX'\#>'_!/A33
MO!F@V*0:?I%A#96$"<"*&-%15&.@"JH_"MDVENRX>,'%%%)U)-W-H4:=-<D5
MH(MG&K;RO3/\1[T?8+,\B(`8P0!@8HHI<\F:.$)*[0"UMUX2+`[`'ITZ>G2D
M.FVC@CR5.3GG/!XZ>G04455W8AJ-]@%A;])DSSD4W^R[=/\`CVB"#'&TD>_\
M^?K112&FD[V'FR4X)B3(Z''.?6E%HI.77H<\$CVHHHV&K-;$@ACC38!@5XC^
MR_\`LC']GCQU\4?&-QX]763\2O&S^('M5TK[.-/S`D7V<-YK>;C8#OPG^Z**
M*N#:V,YT*56I'F6U[?<>S6]I:I\B*=JD8&3@8_\`U4XZ?:[1OBW8/R[F)Q^=
M%%2[MIC48I-6&#2K/<&\A<C(!QV[CW'M3O[/@C&$C"\8&***$W<;C%IZ"?9(
M3(%=<@CD9IXLHP,.I(R>K$]\T44YR:*BEM;H-DTNRE7;Y([G()&,C%$-A"A)
M,8;.?O#/?..>WM114J3>HG&$79)"C3;$'>;=0?8>Y/\`4TOV"W4Y6-0I;)&.
M"?7ZT44<S;L%HQ=TMR.32-/D7`@52>ZY!QV&1Z9X].U.&F6`D,OE`L0.I/&,
MX(]#SU'/3T%%%.[1,8Q:6FPOV"W(PB`=.A-,;1[)^MJ@YZJ,>OI]2?KS1123
M=BI*-]@@TC3H)"\=L/F.<$Y`X`X!X`X'`^O4U))I]F>L"],9'!_.BBEJM;A&
9$+6L1MI6G,Q9K-"2<DD4445%V5RQ['__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
